Effects of Atorvastatin in Suppressing Pulmonary Vascular Remodeling in Rats with Chronic Obstructive Pulmonary Disease

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2023 Jul 17

PMID 37459672

Authors

Yonghong He

Songping Wang

Yuying Li

Jun Deng

Lan Huang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effects of atorvastatin calcium on pulmonary vascular remodeling, the authors explored the regulatory mechanism of Histone Deacetylation Enzyme-2 (HDAC2) in rats with Chronic Obstructive Pulmonary Disease (COPD), and provided a new direction for drug treatment in the progression of vascular remodeling.

Methods: Eighteen female SD rats were randomly divided into control (Group S1), COPD (Group S2), and atorvastatin calcium + COPD (Group S3) groups. A COPD rat model was established by passive smoking and intratracheal injection of Lipopolysaccharide (LPS). Haematoxylin and eosin staining and Victoria Blue + Van Gibson staining were used to observe pathological changes in the lung tissue. The pulmonary vascular inflammation score was calculated, and the degree of pulmonary vascular remodeling was evaluated. The ratio of Muscular Arteries in lung tissue (MA%), the ratio of the vessel Wall Area to the vessel total area (WA%), and the ratio of the vessel Wall Thickness to the vascular outer diameter (WT%) were measured using imaging software. The expression of HDAC2 was measured using western blotting, ELISA (Enzyme-Linked Immunosorbent Assay), and qPCR (Real-time PCR).

Results: Compared with the control group, the degree of pulmonary vascular inflammation and pulmonary vascular remodeling increased in rats with COPD. The WT%, WA%, and lung inflammation scores increased significantly; the expression of HDAC2 and HDAC2mRNA in the serum and lung tissue decreased, and the level of Vascular Endothelial Growth Factor (VEGF) in the lung tissues increased (p < 0.05). Compared with the COPD group, the lung tissues from rats in the atorvastatin group had fewer inflammatory cells, and the vascular pathological changes were significantly relieved. The WT%, WA%, and lung inflammation scores decreased significantly; the expression of HDAC2 and HDAC2mRNA in the serum and lung tissues increased, and the level of VEGF in the lung tissues decreased (p < 0.05).

Conclusion: The present study revealed that atorvastatin calcium could regulate the contents and expression of HDAC2 in serum and lung tissues and inhibit the production of VEGF, thereby regulating pulmonary vascular remodeling in a rat model with COPD.

References

Barnes P, Celli B . Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5):1165-85. DOI: 10.1183/09031936.00128008. View

Putcha N, Drummond M, Wise R, Hansel N . Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015; 36(4):575-91. PMC: 5004772. DOI: 10.1055/s-0035-1556063. View

Young R, Hopkins R, Eaton T . Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2010; 18(114):222-32. DOI: 10.1183/09059180.00005309. View

Hamzeh M, Hosseinimehr S, Khalatbary A, Mohammadi H, Dashti A, Talebpour Amiri F . Atorvastatin mitigates cyclophosphamide-induced hepatotoxicity via suppression of oxidative stress and apoptosis in rat model. Res Pharm Sci. 2018; 13(5):440-449. PMC: 6082033. DOI: 10.4103/1735-5362.236837. View

Barnes P . Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2008; 71:451-64. DOI: 10.1146/annurev.physiol.010908.163257. View

Nie Y, Wu H, Li P, Luo Y, Zhang C, Shen J . Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: to establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2012; 25(5):349-56. DOI: 10.1016/j.pupt.2012.06.004. View

Walsh G . Defective apoptotic cell clearance in asthma and COPD--a new drug target for statins?. Trends Pharmacol Sci. 2007; 29(1):6-11. DOI: 10.1016/j.tips.2007.11.002. View

Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S . Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1998; 18(6):768-76. DOI: 10.1165/ajrcmb.18.6.2980. View

Lee C, Yi E, Lee J, Won C, Lee Y, Shin M . Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia. Eur Respir J. 2012; 41(5):1147-56. DOI: 10.1183/09031936.00050612. View

10.

Archer S, Huang J, Reeve H, Hampl V, Tolarova S, Michelakis E . Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ Res. 1996; 78(3):431-42. DOI: 10.1161/01.res.78.3.431. View

11.

Zhou Y, Tan X, Kuang W, Liu L, Wan L . Erythromycin ameliorates cigarette-smoke-induced emphysema and inflammation in rats. Transl Res. 2012; 159(6):464-72. DOI: 10.1016/j.trsl.2011.09.007. View

12.

Gong F, Miller K . Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res. 2013; 750(1-2):23-30. DOI: 10.1016/j.mrfmmm.2013.07.002. View

13.

Liao J, Laufs U . Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118. PMC: 2694580. DOI: 10.1146/annurev.pharmtox.45.120403.095748. View

14.

He P, Smith A, Gelissen I, Ammit A . The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. Pharmacol Rep. 2019; 71(6):1219-1226. DOI: 10.1016/j.pharep.2019.08.006. View

15.

Lim S . Role of statins in coronary artery disease. Chonnam Med J. 2013; 49(1):1-6. PMC: 3651980. DOI: 10.4068/cmj.2013.49.1.1. View

16.

Ambrosi P, Villani P, Habib G, Bouvenot G . [The statins: new properties]]. Therapie. 2003; 58(1):15-21. DOI: 10.2515/therapie:2003003. View

17.

Murphy D, Forrest I, Corris P, Johnson G, Small T, Jones D . Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol. 2008; 294(3):L592-9. DOI: 10.1152/ajplung.00386.2007. View

18.

Khangura R, Bali A, Jaggi A, Singh N . Histone acetylation and histone deacetylation in neuropathic pain: An unresolved puzzle?. Eur J Pharmacol. 2016; 795:36-42. DOI: 10.1016/j.ejphar.2016.12.001. View

19.

Yang J, Zhou R, Zhang M, Tan H, Yu J . Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response. Molecules. 2018; 23(6). PMC: 6100216. DOI: 10.3390/molecules23061274. View

20.

Lai T, Wu M, Zhang C, Che L, Xu F, Wang Y . HDAC2 attenuates airway inflammation by suppressing IL-17A production in HDM-challenged mice. Am J Physiol Lung Cell Mol Physiol. 2018; 316(1):L269-L279. DOI: 10.1152/ajplung.00143.2018. View